Remove en-us pricing
article thumbnail

How COVID-19 Testing Demand Threw off Thermo Fisher’s Acquisition of Qiagen

Health Advances

The mystery lies in whether this deal will ever be resurrected and at what price. CEO Thierry Bernard noted “very significant demand for products used in COVID-19 testing.” Investors took notice and hedge fund manager Davidson Kempner publicly urged Qiagen to seek a higher price—reportedly pushing for $13.4B—based

article thumbnail

Vital Steps to Cure Mediocre Customer Service: Healthcare Has an Opportunity

Medical GPS

There is a lot of truth in that statement and there’s certainly value in the ‘do as I say’ approach, especially when flying through inclement weather, experiencing en route mechanical failures, and other moments of potential crisis. Acting on sound analytics is the difference between success or not. Co-Founder/COO.

article thumbnail

Who Will Pay for COVID-29? (Or, Who Will Pay to Avert It?)

Bill Of Health

Leer en español. A key policy question, then, is who should pay the price of pandemics — and, ideally, of their prevention. Whereas most social and political actors discursively — and, one can think, sincerely — embraced either the first or the second option, reality disappointingly left us with the third. Leer en español. .